Registered title, quoted from ClinicalTrials.gov
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06471738, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
ECOG ≤ 2
Inclusion criterion 14
Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g/dL, or Platelets ≤ 100 x 10\^9/L, or Absolute neutrophil count (ANC) < 1.5 x 10\^9/L;
Inclusion criterion 10
Lactate dehydrogenase (LDH) > upper limit of normal (ULN) or beta (B)2 microglobulin > ULN;
Inclusion criterion 12
ANC > 1.0 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
Inclusion criterion 15
Platelet count > 50 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
Inclusion criterion 16
Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)
Inclusion criterion 17
Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x ULN
Inclusion criterion 18
Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula
Inclusion criterion 19
Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
Inclusion criterion 20
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
Inclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06471738, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated.
- Stage II, III, or IV disease.
- Able and willing to provide written informed consent and to comply with the study protocol.
- at least one measurable disease.
- Must be in need of therapy as evidenced by at least one of the following criteria:
- Presence of at least one B symptom: Fever (> 38 Celsius [C]) not due to infectious etiology, or Night sweats, or Weight loss > 10% in the past 6 months;
- Fatigue due to lymphoma;
- Splenomegaly (> 13 cm);
- Compression syndrome (ureteral, orbital, gastrointestinal);
- Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g/dL, or Platelets ≤ 100 x 10\^9/L, or Absolute neutrophil count (ANC) < 1.5 x 10\^9/L;
- Pleural or peritoneal effusion;
- Lactate dehydrogenase (LDH) > upper limit of normal (ULN) or beta (B)2 microglobulin > ULN;
- Other lymphoma-mediated symptoms as determined by the treating physician.
- ECOG ≤ 2
- ANC > 1.0 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
- Platelet count > 50 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
- Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)
- Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x ULN
- Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula
- Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
- Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
Exclusion Criteria:
- Known active central nervous system lymphoma or leptomeningeal disease
- Follicular lymphoma with evidence of diffuse large B-cell transformation
- Grade 3b follicular lymphoma
- Any prior history of other malignancy besides follicular lymphoma
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Patients who have undergone major surgery within 14 days
- The researchers believe that it is not advisable for the participant to take part in this trial.
Quoted from ClinicalTrials.gov, NCT06471738, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06471738, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.